Utilities and disutilities for attributes of injectable treatments for type 2 diabetes

European Journal of Health Economics

Volumn 12, Issue 3, 2011, Pages 219-230

  Boye, Kristina S ^a   Matza, Louis S ^b   Walter, Kimberly N ^b   Van Brunt, Kate ^b   Palsgrove, Andrew C ^b   Tynan, Aodan ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Dose frequency; Injection; Patient preference; Standard gamble; Type 2 diabetes; Utilities

Indexed keywords

INSULIN; INSULIN GLARGINE; LIRAGLUTIDE;

ADULT; ARTICLE; ATTRIBUTABLE RISK; CONTROLLED STUDY; COST UTILITY ANALYSIS; FEMALE; HEALTH STATUS; HUMAN; INJECTION; INJECTION SITE REACTION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT PREFERENCE; PRIORITY JOURNAL; UNITED KINGDOM;

ADULT; AGE FACTORS; AGED; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTH STATUS; HUMANS; HYPOGLYCEMIC AGENTS; INTERVIEWS AS TOPIC; MALE; MENTAL HEALTH; MIDDLE AGED; QUALITY OF LIFE; SEX FACTORS; SOCIOECONOMIC FACTORS;

EID: 79958062820     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-010-0224-8     Document Type: Article

References (79)

1. DK Arulmozhi B Portha 2006 GLP-1 based therapy for type 2 diabetes Eur. J. Pharm. Sci. 28 96 108 16488579 10.1016/j.ejps.2006.01.003 1:CAS:528:DC%2BD28Xit1Chur4%3D
2. RE Pratley M Gilbert 2008 Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors Rev. Diabet. Stud. 5 73 94 18795210 10.1900/RDS.2008.5.73
3. BT Srinivasan J Jarvis K Khunti MJ Davies 2008 Recent advances in the management of type 2 diabetes mellitus: a review Postgrad. Med. J. 84 524 531 19017837 10.1136/pgmj.2008.067918 1:CAS:528:DC%2BD1MXivFKrsQ%3D%3D
4. GW Torrance 1986 Measurement of health state utilities for economic appraisal J. Health Econ. 5 1 30 10311607 10.1016/0167-6296(86)90020-2 1:STN:280:DyaL283otVOltQ%3D%3D (Pubitemid 16098443)
5. Torrance, G.W.: Designing and conducting cost-utility analysis. In: Spilker, B. (eds.) Quality of Life and Pharmacoeconomics in Clinical Trials. Lippincott-Raven, Philadelphia (1996)
6. PM Clarke AM Gray A Briggs RJ Stevens DR Matthews RR Holman 2005 Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72) Diabetologia 48 868 877 15834550 10.1007/s00125-005-1717-3 1:STN:280:DC%2BD2M3ltFaqsQ%3D%3D (Pubitemid 40767979)
7. LS Matza KS Boye N Yurgin, et al. 2007 Utilities and disutilities for type 2 diabetes treatment-related attributes Qual. Life Res. 16 1251 1265 17638121 10.1007/s11136-007-9226-0 (Pubitemid 47357727)
8. P McEwan JR Peters K Bergenheim CJ Currie 2006 Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster) Curr. Med. Res. Opin. 22 121 129 16393438 10.1185/030079906X80350 (Pubitemid 43106915)
9. AJ Palmer S Roze WJ Valentine, et al. 2004 The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making Curr. Med. Res. Opin. 20 S5 S26 15324513 10.1185/030079904X1980 (Pubitemid 39349905)
10. E Warren E Weatherley-Jones J Chilcott C Beverley 2004 Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine Health Technol. Assess. 8 iii 1 57 1:CAS:528:DC%2BD2cXlvVamt74%3D
11. H Zhou DJ Isaman S Messinger, et al. 2005 A computer simulation model of diabetes progression, quality of life, and cost Diabetes Care 28 2856 2863 16306545 10.2337/diacare.28.12.2856 (Pubitemid 43942915)
12. RG Bretzel U Nuber W Landgraf DR Owens C Bradley T Linn 2008 Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial Lancet 371 1073 1084 18374840 10.1016/S0140-6736(08)60485-7 1:CAS:528:DC%2BD1cXktVCns7Y%3D (Pubitemid 351436611)
13. HOE 901/2004 Study Investigators Group 2003 Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients Diabet. Med. 20 545 551 10.1046/j.1464-5491.2003. 00999.x (Pubitemid 36886468)
14. T Vilsboll B Brock H Perrild, et al. 2008 Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus Diabet. Med. 25 152 156 18201212 10.1111/j.1464-5491.2007.02333.x 1:STN:280:DC%2BD1c7jtFWhsQ%3D%3D (Pubitemid 351293400)
15. Balena, R., Ratner, R., Berria, R., et al.: Eight weeks of treatment with the long acting, human GLP-1 analogue R1583 improves glycemic control and lowers body weight in subjects with type 2 diabetes mellitus (T2DM) treated with metformin: a double-blind placebo-controlled phase 2 study. Presented at the 68th Scientific Session of the American Diabetes Association, San Francisco (2008)
16. DJ Drucker JB Buse K Taylor, et al. 2008 Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 372 1240 1250 18782641 10.1016/S0140-6736(08)61206- 4 1:CAS:528:DC%2BD1cXhtF2ku7nN
17. Hoffmann-La Roche Ltd: Roche Moves Investigational Diabetes Drug, Taspoglutide, into Phase III Clinical Trials: Positive Phase II Results of Roche and Ipsen's First Once-weekly Human GLP-1 Presented at the American Diabetes Association Congress. Hoffmann-La Roche, Basel (2008)
18. D Kim L MacConell D Zhuang, et al. 2007 Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes Diabetes Care 30 1487 1493 17353504 10.2337/dc06-2375 1:CAS:528:DC%2BD2sXntlWktr4%3D (Pubitemid 46871159)
19. Ratner, R., Nauck, M., Asnaghi, V., et al.: Safety and tolerability of high doses of the long acting, human GLP-1 analogue R1583 in diabetic subjects treated with metformin: a double-blind, placebo-controlled phase 2 study. Presented at the 68th Scientific Session of the American Diabetes Association, San Francisco (2008)
20. RN Greenberg 1984 Overview of patient compliance with medication dosing: a literature review Clin. Ther. 6 592 599 6383611 1:STN:280: DyaL2M%2FgtF2htA%3D%3D (Pubitemid 14064945)
21. Morris, A.D.: Addressing dosing frequency in diabetes: a simple approach to improving adherence to therapy and clinical outcomes. Diabetes Educ. 29, 440-446, 448, 450 (2003)
22. AHP Paes A Bakker CJ Soe-Agnie 1997 Impact of dosage frequency on patient compliance Diabetes Care 20 1512 1517 9314626 10.2337/diacare.20.10.1512 1:STN:280:DyaK2svmtVajsw%3D%3D (Pubitemid 27415025)
23. L Shi M Hodges N Yurgin KS Boye 2007 Impact of dose frequency on compliance and health outcomes: a literature review (1966-2006) Expert Rev. Pharmacoecon. Outcomes Res. 7 187 202 20528445 10.1586/14737167.7.2.187 (Pubitemid 46690969)
24. A Zambanini RB Newson M Maisey MD Feher 1999 Injection related anxiety in insulin-treated diabetes Diabetes Res. Clin. Pract. 46 239 246 10624790 10.1016/S0168-8227(99)00099-6 1:CAS:528:DyaK1MXntlentrY%3D
25. JH Anderson Jr RL Brunelle P Keohane, et al. 1997 Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus Arch. Intern. Med. 157 1249 1255 9183237 10.1001/archinte.157.11.1249 1:CAS:528:DyaK2sXktlWqu7o%3D (Pubitemid 27251653)
26. JH Anderson Jr RL Brunelle VA Koivisto, et al. 1997 Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment Diabetes 46 265 270 9000704 10.2337/diabetes.46.2.265 1:CAS:528:DyaK2sXmtlyksA%3D%3D (Pubitemid 27272261)
27. SG Ashwell C Bradley JW Stephens E Witthaus PD Home 2008 Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes Diabetes Care 31 1112 1117 18339977 10.2337/dc07-1183 1:CAS:528:DC%2BD1cXotVansbc%3D
28. H Linnebjerg PA Kothare Z Skrivanek, et al. 2006 Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes Diabet. Med. 23 240 245 16492205 10.1111/j.1464-5491.2006.01800.x 1:CAS:528: DC%2BD28Xjs1OgtLo%3D
29. J Rex KH Jensen SA Lawton 2006 A review of 20 years' experience with the NovoPen (registered trademark) family of insulin injection devices Clin. Drug Inves. 26 367 401 10.2165/00044011-200626070-00001 1:CAS:528: DC%2BD2sXhs1Wnur8%3D (Pubitemid 43927053)
30. CJ Dunn GL Plosker GM Keating K McKeage LJ Scott 2003 Insulin glargine: an updated review of its use in the management of diabetes mellitus Drugs 63 1743 1778 12904090 10.2165/00003495-200363160-00007 1:CAS:528: DC%2BD3sXntlKisL0%3D (Pubitemid 36999964)
31. C Bradley CJ Gilbride 2008 Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine Diabetes Obes. Metab. 10 Suppl 2 50 65 18577157 10.1111/j.1463-1326.2008.00871.x 1:CAS:528:DC%2BD1cXovFSntLw%3D
32. K Howorka J Pumprla D Wagner-Nosiska H Grillmayr C Schlusche A Schabmann 2000 Empowering diabetes out-patients with structured education: short-term and long-term effects of functional insulin treatment on perceived control over diabetes J. Psychosom. Res. 48 37 44 10750628 10.1016/S0022-3999(99)00074-4 1:STN:280:DC%2BD3c3ht1KltA%3D%3D (Pubitemid 30128566)
33. W Shen JG Kotsanos WJ Huster SD Mathias CM Andrejasich DL Patrick 1999 Development and validation of the Diabetes Quality of Life Clinical Trial Questionnaire Med. Care 37 AS45 AS66 10217393 10.1097/00005650-199904001-00008 1:STN:280:DyaK1M3jtFOntw%3D%3D
34. RT Anderson SE Skovlund D Marrero, et al. 2004 Development and validation of the insulin treatment satisfaction questionnaire Clin. Ther. 26 565 578 15189754 10.1016/S0149-2918(04)90059-8 (Pubitemid 38586458)
35. LN Jorgensen FS Nielsen 1990 Timing of pre-meal insulins in diabetic patients on a multiple daily injection regimen: a questionnaire study Diabetologia 33 A116
36. MA Nauck M Hompesch R Filipczak TDT Le M Zdravkovic J Gumprecht 2006 Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes Exp. Clin. Endocrinol. Diabetes 114 417 423 17039422 10.1055/s-2006-924230 1:CAS:528:DC%2BD28XhtFWqt7vJ (Pubitemid 44620484)
37. S Schwartz D Hassman J Shelmet, et al. 2004 A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge × 6 mm needle versus a 29 gauge × 12.7 mm needle in obese patients with diabetes mellitus Clin. Ther. 26 1663 1678 15598483 10.1016/j.clinthera.2004.10.007 (Pubitemid 39643027)
38. JL Gonzalez GH Verrips M Fekkes RA Hirasing M Groth 1998 Psychological responses to the needle-free injection of insulin with the disposable front-end Medi-Jector (MJ-6) Today's Ther. Trends 16 53 72
39. T Richardson D Kerr 2003 Skin-related complications of insulin therapy: epidemiology and emerging management strategies Am. J. Clin. Dermatol. 4 661 667 14507228 10.2165/00128071-200304100-00001 (Pubitemid 37411982)
40. N Chokrungvaranon T Chentanez RF Arakaki 2007 Clinical experience with exenatide in predominantly Asian and Pacific Islander patients with type 2 diabetes Endocrine 32 311 316 18266113 10.1007/s12020-008-9042-5 1:CAS:528:DC%2BD1cXks1Gltb0%3D
41. A Gafni 1994 The standard gamble method: what is being measured and how it is interpreted Health Serv. Res. 29 207 224 8005790 1:STN:280: DyaK2c3nsVCgsw%3D%3D
42. GW Torrance W Furlong D Feeny 2002 Health utility estimation Expert Rev. Pharmacoecon. Res. 2 99 108 10.1586/14737167.2.2.99 (Pubitemid 34657134)
43. LS Matza K Secnik AM Rentz, et al. 2005 Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent proxy report Qual. Life Res. 14 735 747 16022066 (Pubitemid 40576859)
44. DA Revicki M Wood 1998 Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications J. Affect. Disord. 48 25 36 9495599 10.1016/S0165-0327(97)00117-1 1:STN:280:DyaK1c7lsV2rtQ%3D%3D (Pubitemid 28078968)
45. K Secnik LS Matza S Cottrell E Edgell D Tilden S Mannix 2005 Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United Kingdom Med. Decis. Making 25 56 70 15673582 10.1177/0272989X04273140 (Pubitemid 40139884)
46. GW Torrance D Feeny 1989 Utilities and quality-adjusted life years Int. J. Technol. Assess. Health Care 5 559 575 2634630 10.1017/S0266462300008461 1:STN:280:DyaK3c3js1Kitg%3D%3D (Pubitemid 20153102)
47. EB Bass EP Steinberg HA Pitt, et al. 1994 Comparison of the rating scale and the standard gamble in measuring patient preferences for outcomes of gallstone disease Med. Decis. Making 14 307 314 7808206 10.1177/ 0272989X9401400401 1:STN:280:DyaK2M7gslSiug%3D%3D (Pubitemid 24331323)
48. J Cook J Richardson A Street 1994 A cost utility analysis of treatment options for gallstone disease: methodological issues and results Health Econ. 3 157 168 7921059 10.1002/hec.4730030305 1:STN:280:DyaK2M%2FgsFWnsA%3D%3D
49. DH Feeny GW Torrance 1989 Incorporating utility-based quality-of-life assessment measures in clinical trials. Two examples Med. Care 27 S190 S204 2522159 10.1097/00005650-198903001-00016 1:STN:280:DyaL1M7lvVehsA%3D%3D
50. K Johnston J Brown K Gerard M O'Hanlon A Morton 1998 Valuing temporary and chronic health states associated with breast screening Soc. Sci. Med. 47 213 222 9720640 10.1016/S0277-9536(98)00065-3 1:STN:280:DyaK1czosFGqtg%3D%3D (Pubitemid 28297258)
51. Mauskopf, J.: Utility assessment. In: Chumney, E.C.G., Simpson, K.N. (eds.) Methods and Designs for Outcomes Research. American Society of Health-System Pharmacists, Bethesda (2006)
52. PF Stalmeier 2002 Discrepancies between chained and classic utilities induced by anchoring with occasional adjustments Med. Decis. Making 22 53 64 11837249 (Pubitemid 34087690)
53. MP Rutten-van Molken CH Bakker EK van Doorslaer S van der Linden 1995 Methodological issues of patient utility measurement. Experience from two clinical trials Med. Care 33 922 937 7666706 10.1097/00005650-199509000-00004 1:STN:280:DyaK2Mzps1WmsQ%3D%3D
54. Brooks, R., Rabin, R., de Charro, F. (eds.): The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective. Kluwer, Dordrecht (2003)
55. McDowell, I., Newell, C.: Measuring Health: A Guide to Rating Scales and Questionnaires, 2nd edn. Oxford University Press, New York (1996)
56. RL Kolotkin RD Crosby KD Kosloski GR Williams 2001 Development of a brief measure to assess quality of life in obesity Obes. Res. 9 102 111 11316344 10.1038/oby.2001.13 1:STN:280:DC%2BD3MzpsVClsQ%3D%3D (Pubitemid 33603836)
57. J Albu N Raja-Khan 2003 The management of the obese diabetic patient Prim. Care 30 465 491 14567159 (Pubitemid 36791428)
58. S Heller 2004 Weight gain during insulin therapy in patients with type 2 diabetes mellitus Diabetes Res. Clin. Pract. 65 S23 S27 15315867 10.1016/j.diabres.2004.07.005 1:CAS:528:DC%2BD2cXmslens7g%3D (Pubitemid 39094755)
59. AJ Scheen 2000 Treatment of diabetes in patients with severe obesity Biomed. Pharmacother. 54 74 79 10759290 10.1016/S0753-3322(00)88855-1 1:STN:280:DC%2BD3c3itFSnsg%3D%3D (Pubitemid 30163285)
60. Diabetes Control Complications Trial (DCCT) Research Group 1993 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N. Engl. J. Med. 329 977 986 10.1056/NEJM199309303291401 (Pubitemid 23307905)
61. UK Prospective Diabetes Study (UKPDS) Group 1998 A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy (UKPDS 24) Ann. Intern. Med. 128 165 175
62. Dupuy, H.J.: In: Wenger, N.K., Mattson, M.E., Furberg, C.D., et al. (eds.) Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies, pp. 170-183. Le Jacq, Washington (1984)
63. AJ Rush MH Trivedi HM Ibrahim, et al. 2003 The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression Biol. Psychiatry 54 573 583 12946886 10.1016/S0006-3223(02)01866-8 (Pubitemid 37289444)
64. IDS/QIDS: Instruments in English and multiple translations. http://www.ids-qids.org/index.html. Accessed Mar 17 2009 (2009)
65. Cohen, J.: Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Lawrence Erlbaum, Hillsdale, NJ (1988)
66. JS Garrow J Webster 1985 Quetelet's index (W/H2) as a measure of fatness Int J Obes 9 147 153 4030199 1:STN:280:DyaL2M3oslyisg%3D%3D (Pubitemid 15043191)
67. M Koopmanschap 2002 Coping with type II diabetes: the patient's perspective Diabetologia 45 S18 S22 12136407 1:STN:280:DC%2BD38zoslemsQ%3D%3D
68. RL Kolotkin RD Crosby GR Williams 2003 Assessing weight-related quality of life in obese persons with type 2 diabetes Diabetes Res. Clin. Pract. 61 125 132 12951281 10.1016/S0168-8227(03)00113-X (Pubitemid 37013657)
69. K Blumenschein M Johannesson 1998 Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma Ann. Allergy Asthma Immunol. 80 189 194 9494453 10.1016/S1081-1206(10) 62954-7 1:STN:280:DyaK1c7lsFGmtQ%3D%3D (Pubitemid 28103154)
70. C Green G Kiebert C Murphy, et al. 2003 Patients' health-related quality-of-life and health state values for motor neurone disease/amyotrophic lateral sclerosis Qual. Life Res. 12 565 574 13677501 10.1023/A:1025052609818 1:STN:280:DC%2BD3svjs1WnsQ%3D%3D (Pubitemid 37056048)
71. EF Juniper GR Norman FM Cox JN Roberts 2001 Comparison of the standard gamble, rating scale, AQLQ and SF-36 for measuring quality of life in asthma Eur. Respir. J. 18 38 44 11510803 10.1183/09031936.01.00088301 1:STN:280:DC%2BD3MvmsFChug%3D%3D (Pubitemid 32717429)
72. B Kartman G Gatz M Johannesson 2004 Health state utilities in gastroesophageal reflux disease patients with heartburn: a study in Germany and Sweden Med. Decis. Making 24 40 52 15005953 10.1177/027298X03261563 (Pubitemid 38116856)
73. I Ohsawa T Ishida Y Oshida K Yamanouchi Y Sato 2003 Subjective health values of individuals with diabetes in Japan: comparison of utility values with the SF-36 scores Diabetes Res. Clin. Pract. 62 9 16 14581152 10.1016/S0168-8227(03)00145-1 (Pubitemid 37315890)
74. K Stavem 1998 Quality of life in epilepsy: comparison of four preference measures Epilepsy Res. 29 201 209 9551782 10.1016/S0920-1211(97)00075-2 1:STN:280:DyaK1c3htFGjtQ%3D%3D (Pubitemid 28137599)
75. SD Sullivan DP Lew EB Devine Z Hakim GE Reiber DL Veenstra 2002 Health state preference assessment in diabetic peripheral neuropathy Pharmacoeconomics 20 1079 1089 12456202 10.2165/00019053-200220150-00004 (Pubitemid 36005721)
76. GW Torrance 1997 Preferences for health outcomes and cost-utility analysis Am. J. Manag. Care 3 S8 S20 10180342
77. Drummond, M.F., O'Brien, B., Stoddart, G.L., Torrance, G.W.: Methods for the Economic Evaluation of Health Care Programmes, 2nd edn. Oxford University Press, Oxford (2000)
78. National Institute for Clinical Excellence (NICE): guide to the methods of technology appraisal. NICE, London (2003)
79. K Stein A Fry A Round R Milne J Brazier 2005 What value health? A review of health state values used in early technology assessments for NICE Appl. Health Econ. Health Policy 4 219 228 16466273 10.2165/00148365-200504040-00004 (Pubitemid 43242210)